Expression of the serine protease matriptase and its inhibitor HAI-1 in epithelial ovarian cancer: Correlation with clinical outcome and tumor clinicopathological parameters

Clinical Cancer Research

Volumn 8, Issue 4, 2002, Pages 1101-1107

  Oberst, Michael D ^a   Johnson, Michael D ^a   Dickson, Robert B ^a   Lin, Chen Yong ^a   Singh, Baljit ^a   Stewart, Moira ^b   Williams, Alastair ^c   Al Nafussi, Awatif ^c   Smyth, John F ^b   Gabra, Hani ^b   Sellar, Grant C ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; ENZYME INHIBITOR; HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1; MATRIPTASE; MEMBRANE PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL SURFACE; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR CELL;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MEMBRANE GLYCOPROTEINS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RNA, MESSENGER; SERINE ENDOPEPTIDASES; SURVIVAL ANALYSIS; TRYPSIN; TUMOR CELLS, CULTURED;

EID: 0036554846     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Shi, Y. E., Torri, J., Yieh, L., Wellstein, A., Lippman, M. E., and Dickson, R. B. Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells. Cancer Res., 53: 1409-1415, 1993.
2. Lin, C. Y., Wang, J. K., Torri, J., Dou, L., Sang, Q. A., and Dickson, R. B. Characterization of a novel, membrane-bound, 80-kDa matrix-degrading protease from human breast cancer cells. Monoclonal antibody production, isolation, and localization. J. Biol. Chem., 272: 9147-9152, 1997.
3. Lin, C. Y., Anders, J., Johnson, M., and Dickson, R. B. Purification and characterization of a complex containing matriptase and a Kunitz-type serine protease inhibitor from human milk. J. Biol. Chem., 274: 18237-18242, 1999.
4. Lin, C. Y., Anders, J., Johnson, M., Sang, Q. A., and Dickson, R. B. Molecular cloning of cDNA for matriptase, a matrix-degrading serine protease with trypsin-like activity. J. Biol. Chem., 274: 18231-18236, 1999.
5. Zhang, Y., Cai, X., Schlegelberger, B., and Zheng, S. Assignment of human putative tumor suppressor genes ST13 (alias SNC6) and ST14 (alias SNC19) to human chromosome bands 22q13 and 11q24→q25 by in situ hybridization. Cytogenet. Cell Genet., 83: 56-57, 1998.
6. Takeuchi, T., Shuman, M. A., and Craik, C. S. Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue. Proc. Natl. Acad. Sci. USA, 96: 11054-11061, 1999.
7. Tanimoto, H., Underwood, L. J., Wang, Y., Shigemasa, K., Parmley, T. H., and O'Brien, T. J. Ovarian tumor cells express a transmembrane serine protease: a potential candidate for early diagnosis and therapeutic intervention. Tumour Biol., 22: 104-114, 2001.
8. Kim, M. G., Chen, C., Lyu, M. S., Cho, E. G., Park, D., Kozak, C., and Schwartz, R. H. Cloning and chromosomal mapping of a gene isolated from thymic stromal cells encoding a new mouse type II membrane serine protease, epithin, containing four LDL receptor modules and two CUB domains. Immunogenetics, 49: 420-428, 1999.
9. Oberst, M., Anders, J., Xie, B., Singh, B., Ossandon, M., Johnson, M., Dickson, R. B., and Lin, C. Y. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am. J. Pathol., 158: 1301-1311, 2001.
10. Takeuchi, T., Harris, J. L., Huang, W., Yan, K. W., Coughlin, S. R., and Craik, C. S. Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates. J. Biol. Chem., 275: 26333-26342, 2000.
11. Lee, S. L., Dickson, R. B., and Lin, C. Y. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J. Biol. Chem., 275: 36720-36725, 2000.
12. Fischer, K., Lutz, V., Wilhelm, O., Schmitt, M., Graeff, H., Heiss, P., Nishiguchi, T., Harbeck, N., Kessler, H., Luther, T., Magdolen, V., and Reuning, U. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett., 438: 101-105, 1998.
13. Wilhelm, O., Schmitt, M., Hohl, S., Senekowitsch, R., and Graeff, H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin. Exp. Metastasis, 13: 296-302, 1995.
14. Kuhn, W., Schmalfeldt, B., Reuning, U., Pache, L., Berger, U., Ulm, K., Harbeck, N., Spathe, K., Dettmar, P., Hofler, H., Janicke, F., Schmitt, M., and Graeff, H. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. Br. J. Cancer, 79: 1746-1751, 1999.
15. Chambers, S. K., Ivins, C. M., and Carcangiu, M. L. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int. J. Cancer, 79: 449-454, 1998.
16. Schmalfeldt, B., Kuhn, W., Reuning, U., Pache, L., Dettmar, P., Schmitt, M., Janicke, F., Hofler, H., and Graeff, H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res., 55: 3958-3963, 1995.
17. Corps, A. N., Sowter, H. M., and Smith, S. K. Hepatocyte growth factor stimulates motility, chemotaxis and mitogenesis in ovarian carcinoma cells expressing high levels of c-met. Int. J. Cancer, 73: 151-155, 1997.
18. Sowter, H. M., Corps, A. N., and Smith, S. K. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int. J. Cancer, 83: 476-480, 1999.
19. Fang, X., Gaudette, D., Furui, T., Mao, M., Estrella, V., Eder, A., Pustilnik, T., Sasagawa, T., Lapushin, R., Yu, S., Jaffe, R. B., Wiener, J. R., Erickson, J. R., and Mills, G. B. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer. Ann. NY Acad. Sci., 905: 188-208, 2000.
20. Xu, Y., Gaudette, D. C., Boynton, J. D., Frankel, A., Fang, X. J., Sharma, A., Hurteau, J., Casey, G., Goodbody, A., Mellors, A., et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin. Cancer Res., 1: 1223-1232, 1995.
21. Xiao, Y. J., Schwartz, B., Washington, M., Kennedy, A., Webster, K., Belinson, J., and Xu, Y. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal. Biochem., 290: 302-313, 2001.
22. Shimomura, T., Denda, K., Kitamura, A., Kawaguchi, T., Kito, M., Kondo, J., Kagaya, S., Qin, L., Takata, H., Miyazawa, K., and Kitamura, N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J. Biol. Chem., 272: 6370-6376, 1997.
23. Kataoka, H., Shimomura, T., Kawaguchi, T., Hamasuna, R., Itoh, H., Kitamura, N., Miyazawa, K., and Koono, M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J. Biol. Chem., 275: 40453-40462, 2000.
24. Kataoka, H., Suganuma, T., Shimomura, T., Itoh, H., Kitamura, N., Nabeshima, K., and Koono, M. Distribution of hepatocyte growth factor activator inhibitor type 1 (HAI-1) in human tissues. Cellular surface localization of HAI-1 in simple columnar epithelium and its modulated expression in injured and regenerative tissues. J. Histochem. Cytochem., 47: 673-682, 1999.
25. Kataoka, H., Hamasuna, R., Itoh, H., Kitamura, N., and Koono, M. Activation of hepatocyte growth factor/scatter factor in colorectal carcinoma. Cancer Res., 60: 6148-6159, 2000.
26. Foulkes, W. D., Campbell, I. G., Stamp, G. W., and Trowsdale, J. Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer. Br. J. Cancer, 67: 268-273, 1993.
27. Gabra, H., Taylor, L., Cohen, B. B., Lessels, A., Eccles, D. M., Leonard, R. C., Smyth, J. F., and Steel, C. M. Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours. Br. J. Cancer, 72: 367-375, 1995.
28. Gabra, H., Watson, J. E., Taylor, K. J., Mackay, J., Leonard, R. C., Steel, C. M., Porteous, D. J., and Smyth, J. F. Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis. Cancer Res., 56: 950-954, 1996.
29. Davis, M., Hitchcock, A., Foulkes, W. D., and Campbell, I. G. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res., 56: 741-744, 1996.
30. Launonen, V., Stenback, F., Puistola, U., Bloigu, R., Huusko, P., Kytola, S., Kauppila, A., and Winqvist, R. Chromosome 11q22.3-q25 LOH in ovarian cancer: association with a more aggressive disease course and involved subregions. Gynecol. Oncol., 71: 299-304, 1998.
31. Connolly, K. C., Gabra, H., Millwater, C. J., Taylor, K. J., Rabiasz, G. J., Watson, J. E., Smyth, J. F., Wyllie, A. H., and Jodrell, D. I. Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer. Cancer Res., 59: 2806-2809, 1999.
32. Gudmundsson, J., Barkardottir, R. B., Eiriksdottir, G., Baldursson, T., Arason, A., Egilsson, V., and Ingvarsson, S. Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br. J. Cancer, 72: 696-701, 1995.
33. Gentile, M., Olsen, K., Dufmats, M., and Wingren, S. Frequent allelic losses at 11q24.1-q25 in young women with breast cancer: association with poor survival. Br. J. Cancer, 80: 843-849, 1999.
34. Hampton, G. M., Penny, L. A., Baergen, R. N., Larson, A., Brewer, C., Liao, S., Busby-Earle, R. M., Williams, A. W., Steel, C. M., Bird, C. C., et al. Loss of heterozygosity in cervical carcinoma: subchromosomal localization of a putative tumor-suppressor gene to chromosome 11q22-q24. Proc. Natl. Acad. Sci. USA, 91: 6953-6957, 1994.
35. Gentile, M., Wiman, A., Thorstenson, S., Loman, N., Borg, A., and Wingren, S. Deletion mapping of chromosome segment 11q24-q25, exhibiting extensive allelic loss in early onset breast cancer. Int. J. Cancer, 92: 208-213, 2001.
36. Benaud, C., Dickson, R. B., and Lin, C. Y. Regulation of the activity of matriptase on epithelial cell surfaces by a blood-derived factor. Eur. J. Biochem., 268: 1439-1447, 2001.
37. Enyedy, I. J., Lee, S. L., Kuo, A. H., Dickson, R. B., Lin, C. Y., and Wang, S. Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase. J. Med. Chem., 44: 1349-1355, 2001.